Suven Life SciencesQ1 FY18

Suven Life Sciences Q1 FY18 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹268.65Market Cap: ₹7.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Suven Life Sciences expects a 10% to 15% growth in topline (revenue) and bottom-line (profits) going forward.
  • The CRAMS business growth is linked more to the success of molecules moving through clinical phases than just the number of projects, which typically churns with 30-40 molecules leaving and joining annually.
  • Specialty Chemicals is expected to have minimal growth, around ±5% annually, as it is a mature product line.
  • The launch quantities for commercial molecules are anticipated to exceed previous guidance (around Rs. 60-70 crore annually).
  • Continued investment in NCE (New Chemical Entities) is expected to mature over time, adding value.
  • No visibility beyond six months on clinical timelines and commercial ramp-ups, leading to cautious yet positive growth outlook.
  • Infrastructure expansion supports leveraging existing assets without major capital increases, indicating scalability with current resources.

See what Suven Life Sciences management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no direct mention of any current or planned fundraising through debt or equity in the provided transcript.
  • The company appears to be utilizing spare capital by investing in mutual funds rather than raising new funds.
  • Capital expenditure plans include a Rs.120 crore investment for a new block at Pashamylaram, implying internal funding rather than new external fundraising.
  • The company focuses on leveraging existing infrastructure to manage costs, indicating cautious capital management without reliance on fresh capital raising.
  • No explicit plans or indications of new debt or equity issuance are discussed in this call.

See what Suven Life Sciences management said on order book — free account, 30 seconds.

Capex plans

Yes
- Rs. 120 crore CAPEX planned for creation of a new specialty chemicals block at Pashamylaram, meeting OEL4 requirements (Page 12). - Maintenance CAPEX expected to be Rs. 20-25 crore, roughly 10-15% of regular requirements (Page 12). - Rs. 100 crore investment towards expansion for increased API production capacity from 7.5 tonnes to 75 tonnes per month through phased environmental clearance (Pages 10). - Expansion permissions already obtained for maximum capacity based on plot limits to avoid future licensing needs (Page 10). - Regular CAPEX additions ongoing, in addition to previous Vizag Specialty Chemicals facility capitalization (Page 8). - The R&D infrastructure created is leveraged for new generic ANDA filings; any incremental costs are mostly recurring expenditures (Page 16). Overall, significant capital investment is underway primarily for specialty chemicals facility expansion and infrastructure to support growth in NCE and generic pipelines.

Track Suven Life Sciences — get its next earnings analysis in your feed

How does Suven Life Sciences rank vs peers in Healthcare Services?

Pro feature
ThisSuven Life Sciences
Rev 3Mar 3

How does Suven Life Sciences rank in Healthcare Services?

Compare Suven Life Sciences against every Healthcare Services company (Q1 FY18) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →